Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) shares shot up 7.6% during mid-day trading on Tuesday . The stock traded as high as $3.50 and last traded at $3.41, with a volume of 1,275,612 shares. The stock had previously closed at $3.17.

Several research firms recently issued reports on ANTH. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a report on Wednesday, August 10th. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. HC Wainwright began coverage on shares of Anthera Pharmaceuticals in a research report on Friday, July 8th. They set a “buy” rating and a $10.00 target price on the stock. Finally, FBR & Co restated a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Anthera Pharmaceuticals currently has an average rating of “Buy” and an average target price of $9.58.

The firm’s market cap is $142.92 million. The company’s 50 day moving average is $3.21 and its 200-day moving average is $3.41.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. Equities research analysts predict that Anthera Pharmaceuticals Inc. will post ($1.37) EPS for the current fiscal year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.